Clinical Trials on Melanoma (Skin)

Total 52346 results

National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Southwest Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Institut du Cancer de Montpellier - Val d'Aurelle

Completed

Fotemustine in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Unknown

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
University Hospital Bispebjerg and Frederiksberg

Completed

Fast Track Diagnosis of Skin Cancer by Advanced Imaging Technologies and Tumour Tapestripping

Skin Cancer | Malignant Melanoma

Denmark
Hadassah Medical Organization

Unknown

Early Diagnosis of Malignant Transformation of Pigmentary Skin Lesions

Malignant Melanoma | Skin Neoplasm | Pigmented Nevi

Israel
University of Oklahoma

Completed

Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin

Metastatic Cancer | Melanoma (Skin)

United States
European Organisation for Research and Treatment...

Terminated

Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain

Metastatic Cancer | Melanoma (Skin)

France, Norway, Belgium, Netherlands, United Kingdom, Austria, Czech Republic, Germany, Italy, Portugal, Switzerland
Emory University
National Cancer Institute (NCI); NovoCure Ltd.

Recruiting

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases

Metastatic Melanoma | Melanoma of Unknown Primary | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Mucosal Melanoma | Metastatic Ocular Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Institute of Oncology Ljubljana
Slovenian Research and Innovation Agency

Enrolling by invitation

Electrochemotherapy Induces Changes in the Tumor Microenvironment of Cutaneous and Subcutaneous Metastases in Patients With Cutaneous Melanoma

Cutaneous Malignant Melanoma

Slovenia
National Cancer Institute (NCI)

Active, not recruiting

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm

United States
Thomas Jefferson University

Not yet recruiting

Neoadjuvant Tebentafusp for Uveal Melanoma

Locally Advanced Unresectable Uveal Melanoma

United States
Georgiamune Inc

Recruiting

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Solid Tumor | Melanoma Stage IV

United States
Multitude Therapeutics Inc.

Recruiting

AMT-253 in Patients With Advanced Solid Tumours

Advanced Solid Tumors | Malignant Melanoma

China
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France; Société... and other collaborators

Recruiting

Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors (ENZYMELA)

Cutaneous Melanoma

France
Fox Chase Cancer Center
Incuron

Suspended

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Locally Advanced or Metastatic Melanoma

United States
Hussein Tawbi
Schering-Plough; Eisai Inc.

Completed

Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma (UPCI-07-008)

Malignant Melanoma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
National Cancer Institute (NCI)

Unknown

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Melanoma

Melanoma (Skin)

United States
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma (IMMUQ)

Head and Neck Mucosal Melanomas

France
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases

Head and Neck Melanoma

United States
TILT Biotherapeutics Ltd.

Active, not recruiting

TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma (TUNINTIL)

Metastatic Melanoma

France, Denmark
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

Metastatic Melanoma | Metastatic Uveal Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous... and other conditions

United States
Institut Curie
Genentech, Inc.

Completed

A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes (NeoEpitope)

Breast Cancer | Cutaneous Melanoma

France
University of Utah

Completed

Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma

Cancer

United States
National Cancer Institute (NCI)

Terminated

Drosophila-generated CTL

Metastatic Cutaneous Melanoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Metastatic Cancer | Melanoma (Skin)

United States
Maxim Pharmaceuticals
National Cancer Institute (NCI)

Unknown

Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver

Metastatic Cancer | Melanoma (Skin)

United States, Canada, Germany, United Kingdom
TriSalus Life Sciences, Inc.

Active, not recruiting

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma in the Liver

United States
Melanoma Institute Australia

Withdrawn

Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases (INTRANS)

Melanoma | In-Transit Metastasis of Cutaneous Melanoma

Australia
Delcath Systems Inc.

Active, not recruiting

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Metastatic Uveal Melanoma | Metastatic Ocular Melanoma

United States
National Cancer Institute (NCI)

Terminated

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

Metastatic Uveal Melanoma | Metastatic Ocular Melanoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Metastatic Melanoma | Metastatic Cutaneous Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Mucosal Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Solid Neoplasm | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma... and other conditions

United States
Regeneron Pharmaceuticals
Bristol-Myers Squibb

Completed

CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

Melanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced Melanoma

United States
Regeneron Pharmaceuticals
Bristol-Myers Squibb

Active, not recruiting

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Melanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced Melanoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Refractory Melanoma | HLA-A2 Positive Cells Present

United States
Diwakar Davar
Immunocore Ltd

Not yet recruiting

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Uveal Melanoma

United States
Dana-Farber Cancer Institute
BioMed Valley Discoveries, Inc

Active, not recruiting

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

Uveal Melanoma

United States
University of Colorado, Denver
Karsh Family Research Fund

Active, not recruiting

Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer

Head and Neck Cancer | Malignant Melanoma

United States
Novartis Pharmaceuticals

Completed

A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma

BRAF V600 Mutation Positive Melanoma

China
Immunocore Ltd
Clinigen, Inc.

Available

A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp (Non Applicable)

Uveal Melanoma
Medical University of Vienna

Recruiting

Longitudinal Follow-Up of Patients Treated With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal Melanoma

Uveal Melanoma

Austria
HonorHealth Research Institute
NovoCure Ltd.

Recruiting

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

Uveal Melanoma

United States
M.D. Anderson Cancer Center

Recruiting

Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma

Cutaneous Melanoma

United States
Immunocore Ltd

Active, not recruiting

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Uveal Melanoma

United States, Canada, United Kingdom, Spain, France, Germany, Poland, Australia, Belgium, Italy, Netherlands, Russian Federation, Switzerland, Ukraine

Clinical Trials on Melanoma (Skin)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations